BRAFV600E-driven lung and thyroid cancers are also responsive to combined inhibition of BRAFV600E plus MEK1/2 using dabrafenib and trametinib, which are now FDA-approved standard of care for metastatic NCSLC and thyroid cancer patients [23,24]. Here, MAP2K1 is linked to thyroid gland carcinoma.